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Brain and central nervous cancer presents a significant clinical burden, accounting 
for 2.4% of all cancer deaths.  High grade glioma is particularly deadly, with 5 year 
survival times of 35% or less.  Traditional treatment includes tumor resection followed by 
radiation therapy or chemotherapy.  Aggressive resection is essential in order to prolong 
patient life.  In fact, several studies have shown that life expectancy increases with 
increased extent of resection.  Extent of resection is burdened by the fact that surgeons 
must be careful not to remove functional brain tissue.   
Resection is incomplete more often than not due to lack of visual cues for the 
surgeon.  He must rely on tactile sensation to distinguish tumor from healthy tissue.  
Methods such as intraoperative MRI and CT exist, but these require expensive equipment 
and special training that is not available in all surgical environments.  Some laboratories 
have proposed small molecule dyes to solve this problem, but these are insufficient when 
used in an invasive tumor model.  It was the goal of this research to provide an objective 
cue in the form of a nanoencapsulated visible dye without the need for additional 
equipment of changes to the surgery process itself other than injection of the dye.   
We hypothesized that the nanocarrier would allow staining of the tumor through 
passive targeting by taking advantage of the enhanced permeability and retention effect.  
Once the nanocarriers have reached the desired target, they would not diffuse out into 
healthy tissue due to their large size compared to small molecule dyes, which readily 
diffuse out and stain healthy tissue.   
To test this hypothesis, we prepared and characterized a liposomal nanocarrier 
encapsulating Evans blue dye.  The nanocarrier was tested for safety in vitro and in vivo, 
 xiii 
then used to delineate tumor margins in an invasive rat glioma model in vivo.  
Microscopic analysis was then conducted to ensure only tumor tissue was stained by the 
nanocarrier.  This thesis presents a successful method of tumor border delineation to 
provide surgeons with positive visual cues without the need for changes in surgical 









1.1 Statement of Problem 
Malignant brain cancer, specifically glioma, is a deadly disease with generally 
poor treatment outcomes.  There were approximately 22,000 new cases of brain and 
central nervous system (CNS) cancers in adults in 2008, resulting in a five year survival 
rate of 35%.  Roughly 20% of these cases were glioma with even poorer prognosis [1].  
Malignant glioma is currently the second most deadly cancer in middle aged adults and 
adolescents [2]. Successful treatment of glioma is difficult due to its rapid growth rate 
and tendency to invade into healthy tissue. 
Currently, aggressive surgical resection is the primary method used to extend 
survival for patients suffering from high grade glioma [3-7].  Even with treatment, 
prognosis is poor, resulting in a mean survival time as low as 11 to 14 months [8]. 
However, patient life expectancy increases with an increase in extent of resection [5, 8]. 
Concomitantly, minimizing removal of healthy neural tissue is critical to ensure quality 
of life. As a consequence, total and complete surgical resection of tumors is rare, and a 
vast majority of brain tumors recur, often in close proximity to the resection site [9, 10]. 
A major impediment to achieving greater accuracy in tumor resection stems from 
the absence of clear visual cues demarcating the tumor margin and poor tools to enable 
accurate demarcation of tumor margins. Therefore, neurosurgeons currently rely on 
subjective criteria, such as tactile feedback and slight discoloration, to assess whether 
tissue is healthy or tumor. Presurgical magnetic resonance imaging (MRI) or computed 
tomography (CT) can provide relevant information to plan the surgical procedure, but 
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does not provide real-time information during resection. Intraoperative histology can 
provide surgeons with information about the margins, but this method can be time 
consuming and can only assess whether tissue is healthy or tumor after it is removed 
from the patient. Intraoperative CT or MRI are possible alternatives, providing non-
invasive information about extent of remaining tumor, but are expensive and special 
training is often needed, so these techniques are only available in more advanced surgical 
environments.  Fluorescent probes that stain tumors have been reported but they require 
special equipment for excitation and detection, as well as low light conditions, neither of 
which is optimal in a surgical environment [11-15]. Thus, a method to demarcate tumor 
margins without a significant change to surgical conditions is desired. Demarcation of the 
tumor margin will allow more accurate and complete removal of tumor tissue, 
conceivably leading to extended survival times for patients. 
1.2 Hypothesis 
A method to demarcate tumor margins without a significant change to surgical 
conditions is desired to increase efficiency of resection. Ozawa, Orringer, and their 
respective colleagues have suggested the use of a freely injected visible dye to address 
this challenge [16, 17]. This is an elegantly simple solution; however, the demarcation is 
transient so such a dye must be injected several times during the course of the surgical 
procedure. More importantly, the technique stains healthy tissue in more invasive tumors, 
where a real need for demarcation is present. A non-invasive tumor such as the 9L line 
used by Ozawa and others merely “pushes” healthy tissue out of the way as it grows so 
the tumor margin is already fairly distinguished; the tumor extracellular space and 
vasculature do not interact with the healthy tissue [18]. Clearly, this is not the case with 
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most invasive tumors; diffusion through extracellular space would cause staining of 
healthy tissue, as seen in our experiments with injections of Evans blue (EB) dye 
dissolved in sterile saline.  
Previous studies by our lab have shown that a nanoencapsulated x-ray contrast 
agent will passively but selectively accumulate at the periphery of the tumor [19]. Due to 
their relatively large size (~100-200 nm), these nanoparticles mark the margin stably 
without diffusing away, moving no more than 50 µm from the vessel from which they 
exited [20]. Further, liposomal nanocarriers are Food and Drug Administration (FDA) 
approved for use in cancer for delivery of chemotherapeutics, such as Doxil®, which 
yields predictable circulation times and biodistribution, as well as reduces systemic 
toxicity [21-23]. Our hypothesis is that a nanoencapsulated dye would overcome the 
problem with diffusion seen with small molecule dyes and stably delineate the tumor 
margin since nano-sized particles do not readily diffuse through tissue, even in an 
invasive cancer model. 
1.3 Objectives 
 The purpose of the work in this thesis is to use a nanocarrier encapsulated visible 
dye to provide accurate visual cues for the surgeon to intraoperatively delineate tumor 
margins without the need for MRI, fluorescence, or other equipment.  Emphasis is placed 
on not only efficacy, but also safety.   
 To meet this goal, the following objectives were set: 
1. Design, fabricate, and characterize a nanocarrier that encapsulates a visible dye. 
2. Demonstrate safety in vitro as well as in vivo. 
3. Demonstrate ability of the nanocarrier to demarcate the border of an invasive 




2.1 Cancers of the Brain and Central Nervous System 
  The most common cancers of the brain arise from mutations in the support cells 
of the brain, the glia, and are thus termed glioma. The most common subtype is 
astrocytoma, while oligodenrocytomas are less common and ependymomas the least 
common [24, 25].  Glioma is an aggressive and deadly disease.  There are approxiately 
20,500 new cases of glioma reported and 12,500 deaths caused by glioma each year. 
While glioma account for only about 1.4% of all cancers, they are responsible for 2.4% of 
all cancer deaths [26].  Glioma are graded from Grade I (least malignant) to Grade IV 
(most malignant) [27, 28].  
Grade I tumors (ex. pilocytic astrocytoma) are slow to proliferate and are not 
migratory or invasive, making surgical resection simple compared to advanced grades.  In 
fact, resection is often all that is needed to cure the patient of this malady.  Grade II 
tumors (ex. astrocytoma) proliferate slowly, similar to Grade I, but are infiltrative.  Thus, 
resection may not remove all cancerous cells and recurrence is common after resection.  
It is not unusual for this type of tumor to progress to a Grade III lesion (ex. anaplastic 
astrocytoma), which is characterized by malignancy, rapid proliferation, and nuclear 
atypia.  Resection of these tumors is often followed by radiation and/or chemotherapy.  
Grade IV tumors (ex. glioblastoma) present the greatest challenge in clinic and are 
typically fatal, often taking the lives of their hosts within a year.  These highly malignant 
lesions are characterized by rapid proliferation and large amounts of invasion.  Tumors of 
this grade typically have the ability to rapidly recruit and produce their own vasculature.  
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Tumor growth is so rapid, however, that new vasculature is often not sufficient enough to 
supply blood to the entire tumor; thus, necrotic regions are common in this type of lesion.  
Invasion and infiltration of surrounding tissue often results in satellite tumors in other 
regions of the brain and central nervous system [28, 29]. 
Grade I glioma rarely progress to stage II-IV and thus prognosis is generally 
good; full recovery is not uncommon [30].  Grade II glioma are less malignant and easier 
to treat than higher grade tumors; therefore, they generally have better prognoses with 
median survival times of 5-8 years [28, 31].  Grade III gliomas are more malignant than 
the lower grade tumors, and thus have a lower median survival time of 3 years.  The most 
deadly are the Grade IV glioma with median survival rates of less than a year.  Despite 
advances in cancer treatment and therapy, glioblastoma and other highly malignant brain 
tumors result in death more often than not, with 5 year survival rates of only 35% and 
lower [1].  Some strategies for diagnosis and treatment of brain and central nervous 
tumors are discussed below. 
2.2 Diagnosis and Treatment of Brain Cancer 
Symptoms of glioma are highly varied according to the position, size, and 
invasive characteristics of the particular tumor.  Symptoms can include seizures, 
confusion, memory loss, personality change, other neurological deficits, and headaches, 
though headaches experienced by patients are often indistinguishable from normal 
tension headaches [25].  Patients that present these symptoms generally undergo brain 
imaging for diagnosis. 
CT and MRI are the most common modalities for diagnosing brain tumors.  CT is 
less expensive and often more readily available, but may not always accurately diagnose 
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tumor due to lack of contrast [32].  MRI is much more sensitive and more accurately 
diagnoses tumor.  On T1 weighted MRI, glioma presents as a heterogeneously enhancing 
region surrounded by highly contrasting edema [25].  Functional MRI (fMRI) provides 
information on location of vital function which can aid in surgical planning. Other 
methods that provide additional information about a lesion after initial diagnosis aid in 
treatment. 
Metabolic activity of a tumor can provide insight on type and grade of a tumor 
without biopsy, as well as help monitor response to therapy [33].  Positron Emission 









F-fluoro-ʟ-phenylalanine.  Treatment response can also be monitored indirectly using 
diffusion-weighted imaging and diffusion tensor imaging, which provide insight into 
tumor perfusion and vessel permeability [34].  This information can be used to infer 
tumor grade, though biopsy and histological analysis is needed to confirm grade. 
Grading of a specific tumor influences the approach taken to combat it in clinic.  
Other factors include patient information and overall health, tumor location, extent of 
contrast enhancement (MRI or CT), proliferation indices, genetic alterations, and 
previous surgical or therapeutic interventions [28].  Low grade tumors are often met with 
resection alone, while higher grade tumors get a combination of resection and 
radiotherapy or chemotherapy.  Resection reduces so called “mass effect”, or 
complications associated with increased intracranial pressure due to the mass and volume 
of the bulk tumor.  Radiation therapy or chemotherapy aim to eliminate or reduce the 
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number of cells that were either missed during resection or had already invaded beyond 
the tumor margin and into healthy tissue, where resection is not possible. 
Resection of glioma remains the primary means of treatment to extend patient life 
[3-7, 25].  In fact, studies have shown that more complete resection of tumor correlates to 
greater extension of patient life [5, 8].  Complete resection is difficult, however, due to 
the fact that a surgeon must be careful not to remove functional tissue. 
Resection of brain tumors differs significantly from treatment of tumors in less 
essential organs and tissue.  For example, in breast cancer a surgeon has the option to 
remove the entire breast to ensure every malignant cell is removed without compromising 
health of the individual.  Though this may cause cosmetic issues, it is not essential to the 
life of the patient.  With brain tumors, however, you are limited in the amount of excess 
tissue you can remove. One must be careful not to remove healthy, functional brain tissue 
while maximizing extent of resection.  This is often difficult due to lack of objective 
criteria to distinguish healthy from tumor tissue. 
Currently, surgeons rely on tactile feedback and very slight discoloration of tumor 
tissue to distinguish it from healthy tissue.  Preoperative CT, MRI, and fMRI allow 
planning of surgery, but once surgery has begun the surgeon must rely on his experience 
to distinguish healthy from tumor tissue.  Surgeons use suction to remove tumor tissue, 
which is often less dense and softer than healthy tissue.  Current “intraoperative” methods 
of tumor detection require surgery to pause so that the tissue can be assessed. 
Intraoperative MRI and CT are methods used to assess location of malignant 
tissue during surgery.  Though useful in distinguishing tumor tissue from healthy, surgery 
must be halted for scans to be taken.  Also, these methods require expensive equipment 
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and highly trained surgeons and support staff to operate effectively.  Thus, this 
technology is cost prohibitive and only available in a few surgical environments.  
Another method currently used to assess malignancy of tissue during surgery is 
intraoperative histology.  A surgeon removes a suspect sample from the patient and 
histology is performed on the sample.  The sample is then analyzed by an experienced 
pathologist to determine whether the tissue is cancer or healthy.  There are a few flaws to 
this approach.  First, it is time consuming and surgery must be halted to wait for the 
results.  Second, and more importantly, this method only tells you if you have removed 
healthy tissue after it has been removed.  Thus, the method may not prevent a surgeon 
from removing functional tissue. 
After resection, it is common to follow up with radiation therapy or chemotherapy 
to get rid of any remnant cancer cells.  These cells could have been left behind due to 
incomplete resection or could have invaded away from the bulk tumor into healthy tissue.  
Radiotherapy is commonly used for adults, but used much less frequently in children to 
avoid developmental complications [32].  Radiation treatment after resection has been 
shown to increase survival in patients with Grade IV glioma up to 9 months [35, 36].  
Radiotherapy must be used with caution in elderly patients; reduced doses and frequency 
of treatment are often required.  Thus, median survival is only marginally increased from 
16.9 weeks to 29.1 weeks [37].  Even with radiation treatment, up to 90% of tumors recur 
at the original tumor site [38], so other methods must be explored to increase survival. 
Chemotherapy is becoming more common for treatment of glioma with new 
advances in available drugs and delivery methods.  Common chemotherapeutic drugs 
include temozolomide injections and carmustine delivered in the form of Gliadel Wafers.  
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Temozolomide treatment after resection shows moderate increases in survival time, and 
concomitant radiotherapy and temozolomide treatment after resection results in a 2 year 
survival rate increase of approximately 16% compared to radiation alone [36].  Use of 
Gliadel Wafers, manufactured by MGI Pharma, leads to increased survival of 2-3 months 
[39].  However, these increases in survival are still marginal so better treatment regiments 
are needed to extend patient life.   
Though resection is often supplemented with radiation therapy or chemotherapy, 
resection is still the primary, gold standard treatment to increase patient survival time.  It 
has been shown that increasing completeness of resection at the primary tumor site could 
lead to increased survival [5, 8].  However, resection is complicated by the fact that 
tumor tissue is often similar in texture and color to healthy tissue.  Since surgeons must 
remove as much of the bulk tumor as possible while preserving healthy tissue, there is a 
clinical need for objective means of distinguishing tumor from healthy tissue.  This could 
be achieved by staining tumors in vivo to provide visual contrast between tumor and 
healthy tissue. Some recent work in staining tumors to provide objective criteria is 
discussed below. 
2.3 Recent Work in In Vivo Tumor Staining 
There have been many attempts to stain tumors in vivo using small molecule 
visible and/or fluorescent dyes.  Initially, use of vital dyes for tumor resection aimed at 
tracing lymph drainage to indicate sentinel lymph nodes (reviewed by Bostick and 
Giuliano [40]).  Tumors such as melanoma and some forms of breast tumors are known 
to migrate or invade into lymph nodes, where they go on to metastasize into other tissues 
in the body.  For this reason, sentinel lymph nodes are often removed during tumor 
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resection. Morton et al attempted to stain and detect sentinel lymph nodes using various 
dyes, including methylene blue, isosulfan blue, patent blue-V, cyalume, and fluourescein 
[41].  Many of these dyes, when injected, diffused throughout the tissue making lymph 
node detection impossible.  However, 2 dyes, patent blue-V and isosulfan blue, remained 
in the lymphatics without diffusing throughout the tissue, allowing tracking of sentinel 
lymph nodes. 
Use of the previously mentioned dyes in clinic allowed surgeons to precisely 
remove sentinel lymph nodes in melanoma and breast cancers, as well as other solid 
tumors where metastasis through lymph vessels was suspected [41-44].  Tanaka et al 
sought to use fluorescent tags to achieve the same goal with greater sensitivity [45].  
Indocyanine green, an FDA approved dye that fluoresces in the near infrared range, was 
adsorbed to human serum albumin and injected peri-tumorally.  The dye then travelled 
through the lymph to sentinel lymph nodes and was detected using fluorescent 
microscopes.  Though more sensitive than methods using visible dyes, this method 
requires introduction of fluorescence activating and detecting equipment, as well as 
alteration of the lighting in the surgical environment.  Typical halogen lights used in 
modern surgical settings emit not only visible light but light in the near infrared range as 
well.  Therefore, halogen lights cannot be used without introducing interfering infrared 
radiation. 
Since the vasculature of brain tumors have compromised blood brain barrier 
(BBB) and endothelial cell linings, small molecules and nano-scale particles extravasate 
into tumor intracellular space.  Once the molecules extravasate, they do not readily leave 
the extracellular space due to a disorganized or non-existent lymph drainage system in 
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the tumor.  This phenomenon is known as the enhanced permeability and retention (EPR) 
effect [46, 47].  The EPR effect allows intravenously injected drugs and contrast agents to 
passively target and accumulate in tumors.  This method was and is still used by 
researchers to deliver agents that dye tumors in vivo. 
The first attempts to stain tumors in vivo were done using fluorescent compounds.  
Fluorescein was used early on, but requires ultraviolet radiation to detect and undergoes 
rapid clearance due to it being a small molecule dye [48].  Laser activated dyes were 
explored next, but these dyes did not stain tumors sufficiently to mark the margins with 
enough precision and, again, rapid clearance was a problem [49, 50].  Indocyanine green 
was explored with some success by Hansen and colleagues [51].  Tumor bearing animals 
received indocyanine green intravenously.  Tumors were visualized using near infrared 
equipment and resection was performed based on tissue fluorescence.  However, residual 
tumor was discovered after resection. 
Other attempts at marking tumors used Cy5.5 dye conjugated to iron oxide 
particles [12].  This allowed MRI contrast as well as fluorescence contrast, allowing both 
preoperative and intraoperative detection of tumors.  Nguyen and collegues used similar 
Cy5 dye conjugated to cell penetrating peptides to fluorescently stain tumors [15].  Pham 
and colleagues went as far as to synthesize a water-soluble near infrared dye for 
conjugation to nanoparticles and use for tumor detection [13].  This dye was more 
fluorescent than previously available dyes so detection of tumor was more sensitive.  
Qian et al addressed the sensitivity issue by employing Raman spectroscopy to detect 
their tumor targeting agent [52]. 
 12
Though all of these methods were effective to an extent, they all required 
specially adapted equipment such as fluorescence excitation lasers or diodes and 
detection equipment, as well as special lighting conditions.  It would be beneficial if one 
could employ a means of tumor detection that did not require these changes to the 
surgical environment.  Thus, the next logical step in tumor staining was attempting to 
stain them using visible dyes. 
One of the first attempts to stain brain tumors with a visible dye was performed 
by Ozawa and colleagues [16].  Bromophenol blue was injected intravenously into 
animals bearing 9L glioma tumors.  While the injections did result in tumor staining with 
no adverse effects to the animal, there were some problems.  The dye was rapidly cleared 
from the tumor, so extent of staining was highly temporally dependent.  The more 
vascularized border region of the tumor is the first area of the tumor to clear small 
molecule dyes.  Thus, in the bromophenol blue experiments, the margins of the tumors 
were only distinguishable momentarily. Orringer and colleagues performed similar 
experiments using Coomassie blue and a “window” implanted into the skull to view the 
staining in real time [17].  These experiments showed similar results to those using 
bromophenol blue.  But there is one fatal flaw to these approaches. 
Attempts to stain tumors with small molecule dyes thus far have used non-
invasive tumor models such as rat 9L glioma.  These tumors do not interact with 
neighboring tissue; they merely push healthy tissue out of the way as they grow [18].  
Thus, they are inherently delineated and do not accurately mimic those tumor seen in 
clinic.  Clinically relevant tumor models invade neighboring tissue and degrade 
extracellular matrix.  This blurs the line between healthy and malignant tissue and allows 
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small molecule dyes to diffuse into healthy tissues (data presented in results section).  
Encapsulation of a small molecule dye in a nano-scale particle could possibly be used to 
solve this problem. 
2.4 Nanocarriers for Delivery of Chemotherapeutic and Contrast Agents to Tumors 
2.4.1 Advantages of Nanocarriers 
Nanoparticles are structures that have at least 1 nano-scale dimension (1 to several 
100 nm).  In nano-medicine, these particles have been employed to deliver 
chemotherapeutic drugs for treatment of cancer and contrast agents for medical imaging.  
Nanoparticles decrease systemic exposure to the injected agent compared to freely 
injected compounds, which often leads to decreased systemic toxicity and lessens other 
adverse effects.  Nanoparticles allow passive targeting to areas of interest with 
compromised, leaky vasculature, such as that present in tumors. 
 Passive targeting of tumors by nanoparticles occurs via the phenomenon termed 
the enhanced permeability and retention (EPR) effect [46, 47].  Rapidly growing tumor 
lesions require rapid angiogenesis to sustain their high rate of metabolic activity.  Vessels 
that grow in these lesions grow so rapidly and in such a disorganized manner that tumor 
vasculature is often unorganized and leaky.  Leaky vasculature results from the rapid and 
insufficient proliferation of endothelial cells, which line blood vessels, and pericytes, 
which help to maintain impermeable sections of the vasculature such as the BBB.  This 
results in blood vessel fenestrations on the order of several hundred nanometers 
compared to the 5-10 nm present in healthy tissue [53].  Nanoparticles are free to leak 
through these fenestrations into the tumor interstitium, but are too large to leak into 
healthy tissue [54, 55]; the result is lowered systemic exposure to the encapsulated 
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molecules.  Retention of nanoparticles occurs due to the fact that tumor tissue often has 
compromised or insufficient lymphatic drainage [46].  Rapid proliferation of tumor cells 
results in pinching off of lymph vessels so drainage cannot occur.  The combination of 
the leaky vasculature and poor lymph drainage is responsible for the EPR effect.  
Nanoparticles not only help in getting the molecules of interest to the tumor, but ensure 
that they do not diffuse out of the target into healthy tissue.  
Freely injected small molecule dyes tend to diffuse rapidly in invasive tumors, 
often resulting in healthy tissue staining.  One way to overcome the problem of diffusion 
is to encapsulate the small molecule dye in a nanoparticle.  Nanoparticles are small 
enough to still accumulate in tumors due to the EPR effect, but they are large enough that 
they do not readily diffuse through tissue.  In fact, nanoparticles that extravasate into 
tumors through leaky vasculature often remain within 50 µm of the vessel through which 
they exited [20].   
Several types of nanoparticles have been developed that successfully encapsulate 
and deliver small molecule drugs and contrast agents to tumors, including dendrimers, 
carbon nanotubes, metallic nanoparticles, polymeric nanoparticles, and liposomes. 
2.4.2 Dendrimers 
 Dendrimers are globular or spherical multi-branched nanoparticles that resemble 
the branches of a tree; they are composed of synthetic polymers such as polyamidoamine, 
polyethylene oxide, glycerol, and succinic acid, or natural polymers, such as amino acids, 
nucleotides, or sugars [56, 57].   Having many branches increases the surface area for 
conjugation of targeting molecules, chemotherapeutic agents and other drugs, and 
contrast agents.  Dendrimers have been used to deliver chemotherapeutics and contrast 
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agents, as well as for photodynamic therapy and even gene therapy for treatment of 
cancer [57].   
Dendrimers are versatile structures that enable conjugation of targeting moieties 
and protective surface modifications.  Drugs and other small molecules can be 
encapsulated via covalent binding to the branches or can be weakly associated with the 
core.  The core can accommodate hydrophobic or hydrophilic drugs depending on the 
surface chemistry of the core itself; molecules can be held by hydrophobic or hydrophilic 
interaction, as well as electrostatic interactions and hydrogen bonding [58].  However, 
binding through these methods result in particles that leak their contents rather quickly in 
solution, as seen when researchers attempted to encapsulate doxorubicin in this manner 
[59].  After drug loading, each dendrimer encapsulated an average of only 6.5 molecules 
of doxorubicin.  When placed in isotonic solution, these molecules quickly dissociated 
from the dendrimer core.  Other chemotherapeutic dendrimers include those bound to 
paclitaxel [60] and methotrexate [61].  Both of these examples, in addition to a 
chemotherapeutic, also contained the targeting small molecule folate.  Folate receptor is 
often overexpressed on cancer cell surfaces enabling targeting via the folate molecule.  
Therapeutic effect was greater in each case than treatment with the free molecule version 
of their respective chemotherapeutic. 
Dendrimers have been used as delivery methods for contrast agents as well.  
Olson and colleagues conjugated gadolinium chelates to dendrimers containing cell 
penetrating peptides to monitor the activity of proteases in vivo via MRI [62].  Another 
dendrimer was designed by Konda and colleagues [63].  The dendrimer contained both 
folate and a gadolinium chelate and allowed visualization of ovarian tumors in animals.  
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Fluorochromes have also been conjugated to dendrimers to enable fluorescence 
monitoring of physiological activity of cells in tumors [57].   
The major drawback to dendrimers for use in our research is that in order to stably 
encapsulate drugs and contrast agents, one must covalently bind the agent to the polymer.  
This not only makes synthesis more difficult, but also results in a decreased total payload 
compared to other nanoparticles such as liposomes or polymeric nanoparticles with 
aqueous cores (discussed below).  Also, when dealing with dyes, slight alteration to the 
structure through binding alters the resonance of the atoms within the molecule.  Altering 
the resonance can change the wavelengths of visible light the molecule absorbs and 
reflects, thus changing the color of the dye.  This not desirable in our application since we 
want to maintain the deep, dark blue of the Evans blue molecule we used to dye the 
tumor. 
2.4.3 Carbon Nanotubes 
 Carbon nanotubes are single- or multi-walled cylindrical cage structures made up 
of benzene rings.  Carbon nanotubes are thus extremely hydrophobic so surface 
modification, such as coating with PEG, is required to make them soluble in aqueous 
solutions.  They have been used to encapsulate chemotherapeutics, target tumors, and 
deliver DNA or siRNA to cancer cells.   
Carbon nanotubes have been used to encapsulate chemotherapeutics such as 
doxorubicin [64], resulting in successful treatment of tumors.  Doxorubicin was also 
bound to PEG coated nanotubes in a pH dependent manner [65].  The binding was stable 
at physiological pH, but allowed release of the drug in acidic conditions like those 
present in endosomes or lysosomes of cells.  When treated with these nanoparticles, 
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MCF-7 breast cancer cells and U87MG human glioblastoma cells showed high levels of 
cell death in vitro. 
Nanotubes targeted with RGD peptides were used to target integrin positive 
tumors in a mouse model using the U87MG human glioblastoma cell line.  Nanotubes 
were coated with PEG molecules, which were then bound with RGD peptide [66].  
MicroPET images of tumor bearing mice demonstrated selective delivery of targeted 
nanotubes to the tumor site.   
Carbon nanotubes have been used effectively to deliver DNA in vivo.  Folic acid 
coated nanotubes were used to deliver small DNA segments into folate receptor over-
expressing HeLa cells [67].  The cells were then exposed to pulses of NIR radiation to 
cause endosomal release of the DNA nanotubes, which allowed DNA to then enter the 
nucleus of the cells.  Minimal toxicity of the nanotubes was observed, but the long term 
effects of carbon nanotubes have yet to be discovered.  
Carbon nanotubes have been used to deliver siRNA to silence telomerase reverse 
transcriptase (TERT) function in a murine tumor model [68].  Nanotubes with the anti 
TERT siRNA induced tumor cell growth arrest, resulting in longer survival times for 
nude mice inoculated with HeLa tumors.   
In vivo use outside of a laboratory environment relies on the further investigation 
of the long terms effects of carbon nanotubes in the body.  Little is known about their 
long term fate after injection and chronic complications that may develop. 
2.4.4 Metallic Nanoparticles 
 Nanoparticles made of metals such as gold and iron can be used to encapsulate 
small molecules.  Gold nanoparticles can take the shape of spheres, rods, and cubes or 
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cages.  Generally, the only way to “encapsulate” molecules using gold is to attach the 
desired molecule to the surface of the particle either covalently or through hydrophobic 
interactions.  This limits their utility as delivery vectors.  Though gold nanoparticles can 
be used to encapsulate molecules, their primary use in experimental cancer treatment 
methods is tumor ablation or activation of thermosensitive nanocarriers.   
Gold nano-rods and shells can be tuned via alteration of dimensional ratios to 
generate heat in response to stimulation by different frequencies of light [69, 70].  The 
most useful of these are rods and shells that respond to near infrared radiation.  Near 
infrared light can penetrate soft tissue up to 10 cm with little loss of energy due to 
minimal absorption and scattering by intrinsic pigments [71].  Thus, it can be used to 
stimulate gold nanoparticles to generate local hyperthermia of several degrees which 
could be utilized for initiating triggered release of encapsulated agents from 
thermosensitive nanoparticles.  Paasonen et al. has provided a proof of concept of this 
method [69].  Gold nanoparticles were incorporated into calcein loaded liposomes.  The 
liposomes were stable at 37°C, and upon illumination with near infrared light, localized 
heating occurred resulting in calcein release.   
The use of thermosensitive nanoparticles in conjunction with gold nanorods has 
been shown to improve efficacy of nanocarrier delivered doxorubicin in combating 
cancer.  Agarwal and colleagues used this method to treat U87 tumors in mice [72].  
Treatment with thermosensitive liposomes triggered by gold nanorod heating caused 
greater exposure of the cells of the tumor to the doxorubicin encapsulated, thus creating 
more tumor cell death and longer survival times in mice compared to doxorubicin 
liposome treatment alone.  
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 Iron oxide (IO) nanoparticles are similar to gold nanoparticles in that they require 
conjugation of the desired molecules to the surface of the particles.  Though this allows 
the option of transporting small molecule dyes and drugs, IO particles are generally used 
as MRI imaging contrast agents; they appear as hypointense regions on MRI images [73].  
Not only have IO nanoparticles been used to visualize tumors, but they have also been 
used to track specific cell types such as stem cells by adhering appropriate targeting 
molecules [74].   
2.4.5 Polymeric Nanoparticles 
 Polymeric nanoparticles are composed of natural or synthetic polymers such as 
poly(lactide-co-glycolide) (PLGA), polylactic acid (PLA), poly caprolactone (PCL), and 
chitosan.  The most common polymer nanoparticles are nanospheres, which are solid, or 
nanocapsules, which contain a hollow or aqueous central core [75].  Both are well suited 
for encapsulation of small molecules.  Depending on the chemistry of the nanoparticle, it 
can be used to encapsulate hydrophilic or hydrophobic molecules.  Polymeric 
nanoparticles have even been used to encapsulate proteins and nucleic acids [76].  
Surface modifications allow attachment of targeting moieties, such as RGD or folate, or 
protection from the MPS by attaching PEG chains (discussed below).   
One advantage of polymeric nanoparticles is that one can tune the rate of 
degradation of the particle by varying the ratio of biodegradable polymers.  However, a 
major disadvantage is that many of the manufacturing methods for polymer nanoparticles 
require use of toxic solvents.  These must be extensively rinsed and removed before use 
in vivo.  Though promising as molecule delivery agents, there are no polymeric 
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nanoparticles currently approved by the FDA for use in treatment of cancer, though there 
are several in clinical trials at time of writing [77]. 
2.4.6 Liposomes 
Liposomes are spherical nanoparticles made up of phospholipids in a lipid bilayer, 
similar to that of cells.  This makes them highly biocompatible.  In fact, almost all of the 
nanoparticles that are FDA approved for use in humans are liposomal formulations.  
Liposomes can be used to encapsulate large amounts of hydrophilic drugs in the aqueous 
core or hydrophobic drugs in the lipid bilayer.  Liposomes are by no means cutting edge 
technology, having been first developed in the 1960’s [78], but their utility still remains.  
Since their inception, liposomes have been used extensively both in clinic and in 
laboratories to encapsulate drugs and contrast agents. 
Some of the first nanoscale therapeutics approved for human use were liposomal 
nanoparticles that encapsulate cytotoxic anthracycline-derived antitumor drugs.  
Myocet™, liposomal doxorubicin, and DaunoXome™, liposomal daunorubicin, are 
indicated for use as anticancer agents.  Packaging chemotherapeutic drugs in liposome 
vessels allows for accumulation in the tumor while reducing the deadly cardiotoxicity 
associated with freely delivered anthracyclines.  Newer formulations of these drugs, like 
Doxil™, are coated with polyethylene glycol (PEG) to protect them from clearance by 
the MPS thereby prolonging circulation time in the bloodstream.  So-called sterically 
stabilized or “Stealth” liposomes are able to evade opsonization and MPS clearance, 
which is discussed in the next section. 
Contrast agents have also been encapsulated in liposomes.  In studies conducted 
by Karathanasis el al., an iodine contrast agent (Visipaque 320, GE Healthcare, 
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Milwaukee, WI) was encapsulated in 100 nm liposomes and delivered to rats that were 
inoculated with 13762 MAT B III breast tumors.  Mammography was performed on a 
clinical mammography system (Senographe 2000D, GE Healthcare) for three consecutive 
days.  Images were used to calculate the amount of enhancement and approximate 
accumulation rate of the iodine liposomes.  Animals were then separated into two groups.  
Animals in the “good prognosis” group had rapid and intense iodine enhancement in their 
mammography images, and were hypothesized to respond better to subsequent treatment 
with liposomal doxorubicin than those in the “bad prognosis” group, exhibiting slower, 
less pronounced iodine enhancement.  Animals were then treated with liposomal 
doxorubicin and tumor growth was monitored.  After treatment, tumor growth rates 
proved to be much slower in the good prognosis group, resulting in longer survival times 
than the bad prognosis group.  
Karathanasis et al was able to monitor treatment with liposomal 
chemotherapeutics by using a multifunctional liposomal nanoparticle that encapsulated 
both iodine (contrast agent) and doxorubicin (chemotherapeutic) [79].  Mammographic 
imaging after administration of these nanoparticles enabled real time, non-invasive 
assessment of accumulation of drug within tumors.   Having an a priori knowledge of the 
loading of each material allowed quantification of doxorubicin delivery to the area of 
interest.  The encapsulation of iodine not only allowed one to track the accumulation of 





2.5 Nanoparticle Surface Modifications 
The mononuclear phagocyte system (MPS) (formerly known as the 
reticuloendothelial system, or RES) is responsible for removal of macromolecules from 
the blood circulation [80].  The system is composed of blood monocytes, tissue 
macrophages, bone marrow progenitors, Kupffer cells of the liver, and macrophages in 
the spleen.  Unprotected nanoparticles are cleared from the circulation by the MPS in as 
little as 2-3 hours.  Though the circulation of these nanoparticles is much greater than that 
of the freely injected molecules which they encapsulate (as little as 5 minutes for drugs 
like doxorubicin), the short circulation times often do not allow enough time for 
sufficient accumulation of nanoparticles in passively targeted tumor tissue.  Modification 
of the surface of the nanoparticle can help evade the MPS, resulting in longer circulation 
times and thus higher accumulation in target tissue. 
The versatility of nanoparticles not only lies in the ability to package small 
molecules, but also in the many types of surface modifications that can be employed.  
Stealth liposomes containing the hydrophilic polymer PEG or polysaccarides on their 
surface can be used to protect nanoparticles from MPS clearance.  These molecules are 
greatly hydrophillic and effectively create a layer of water surrounding the nanoparticle, 
reducing exposure to blood proteins and thus preventing opsonization of the nanoparticle.  
Opsonization marks macromolecules for phagocytosis by immune cells.  The coating also 
reduces exposure of the nanoparticle to the immune cells themselves.  Coatings can aid in 
steric stabilization of nanoparticles, as well as prevent interactions between nanoparticles 
such as those that could lead to agglomeration. 
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Surface modifications allow one to make hydrophilic, hydrophobic, or 
amphipathic nanoparticles.  Other surface modifications allow attachment of ligands such 
as proteins, antibodies, peptides, nucleic acids, and other small molecules that turn 
nanoparticles into cell specific targeting vehicles [81-83].   
One example of molecular targeting of nanoparticles is the use of surface bound 
folate on PEGylated stealth liposomes to target 9L glioma, which over-express folate 
receptors [84].  Though these nanoparticles proved promising in vitro, their use in vivo 
did not produce the anticipated increased efficacy over non-targeted stealth liposomes 
[85].  The presence of folate on the surface on the liposomes counteracted the stealth 
nature of the PEGylated liposomes, allowing opsonization and accelerated clearance from 
the blood stream.  McNeeley et al proposed a solution using longer cleavable PEG chains 
to mask the folate molecules until accumulation in the tumor occurred [86].  PEG 
molecules with molecular weight of 5000 Daltons were bound to the liposome surface via 
a cleavable disulfide bond.  The longer PEG chains masked the folate targeting 
molecules, which were attached to 2000 Dalton PEG molecules.  The liposomes were 
able to evade the MPS and accumulate in the tumor via the EPR effect.  Later, cysteine 
was delivered to cleave the disulfide bond and detach the PEG5000 coating.  This exposed 
the folate molecules and allowed them to bind to the folate receptors of the target 9L 
gliomas cells, resulting in increased uptake and cell death compared to control non-
targeted stealth liposomes. 
2.6 Conclusion 
Several types of nanoparticles could be used to deliver a small molecule visible 
dye to a tumor to stain it.  However, in order to rapidly employ such a particle in clinic, 
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the nanoparticle used should be biocompatible and safe for use in humans.  Carbon 
nanotubes show promise, but little is known about their long term biocompatibility.  It is 
likely that dendrimers would not stably encapsulate sufficient amounts of dye to 
effectively stain the tumor.  Metallic nanoparticles have similar problems to carbon 
nanotubes; though they are inert, many of the particles remain within the body 
indefinitely after treatment, making chronic complications probable, especially with 
multiple injections.  Polymeric nanoparticles are likely safe, but none have been FDA 
approved for use in cancer therapy at this time.  Liposomes have been FDA approved for 
many drug and contrast delivery applications, including chemotherapy and treatment of 
fungal infections.  Thus, we opted to employ liposomal nanocarriers to encapsulate a 
visible dye for tumor border delineation in vivo.  In the following sections, a method of 




METHODS AND MATERIALS 
3.1 Choosing a Dye and Perceived Luminance 
 Dyes were evaluated for perceived luminance, which estimates the darkness of a 
color. Dyes were dissolved in phosphate buffered saline (PBS) at the same concentration 
(m/v), dilute enough for all dyes to remain translucent when contained in a 1.5 mL 
microcentrifuge tube.  An image was taken of all the dyes together to ensure consistent 
lighting conditions.  RGB values were measured in 3 places for each dye using the color 
picker tool in Photoshop (Adobe, San Jose, CA) and averaged. Luminance was calculated 
via the following equation [87]: 
(1) 0.299*R + 0.587*G + 0.114*B 
3.2 Liposomal Nanocarrier Preparation 
Liposomal nanocarriers were prepared using a mixture of 1,2–Dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) (Genzyme, Cambridge, MA), cholesterol (Sigma-
Aldrich, St Louis, MO), and N-(carbonyl-methoxypolyethyleneglycol-2000)-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (MPEG-2000-DSPE) (Genzyme) in a 
55:40:5 molar ratio dissolved in ethanol. Nano-EB particles were made by hydrating the 
lipid mixture using 75 mg/ml of Evans blue (Alfa Aesar, Ward Hill, MA) in PBS while 
blank liposomes were made by hydrating with PBS alone. The solution was stirred at 
60
o
C for 120 minutes then dialyzed overnight against isosmolar PBS to remove ethanol. 
The liposomes were resized by placing the suspension in a Branson 1510 bath sonicator 
(Branson Ultrasonics, Danbury, CT) for 120 minutes at 60
o
C. Nano-EB particles were 
then run through a Sepharose CL-4B (GE Healthcare, Pittsburgh, PA) size exclusion 
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chromatography column to remove excess, unencapsulated dye.  The filtrate was run 
through a 500kD MWCO MicroKros diafiltration cartridge (Spectrum Laboratories, 
Rancho Dominguez, CA) to remove volume gained in the column.   
3.3 Liposomal Nanocarrier Analysis and Characterization 
Liposomal nanocarriers were analyzed to obtain size distribution and lipid to dye 
ratio, as well as for stability in conditions similar to those encountered in vivo. Size 
distribution of the liposomal nanocarriers was determined using a Zetasizer Nano ZS90 
dynamic light scattering (DLS) particle sizer (Malvern Instruments Ltd, Worcestershire, 
UK).  
Lipid to dye ratio was calculated as amount of lipid divided by amount of dye 
(mg/mg). First, the amount of encapsulated dye in the liposome solution was determined 
by measurement of absorbance of EB.  Liposomes were lysed in 0.8% Triton X100 to 
release their contents and absorbance was measured at 610 nm using a Synergy HT Plate 
Reader (BIO-TEK, Winooski, VT) and compared to a standard curve.  
Final lipid concentration in the liposomal nanocarrier suspension was obtained by 
quantifying the fluorescence of a reporter molecule included in the original liposome 
mixture.  β-DPH-HPC (Invitrogen, Carlsbad, CA) was included in the liposome mixture 
at a concentration of 0.01 mol%.  After liposome preparation was complete, lipid and dye 
in a 100 µL sample were separated via Folch extraction [88]. Dried lipid extract was 
resuspended in ethanol and fluorescence was measured in a Synergy HT Plate Reader 
(BIO-TEK, Winooski, VT) (Excitation: 360 nm Emission 460 nm). A standard curve of 
known concentrations of β-DPH-HPC was used to calculate the amount of lipid present 
in the mixture. 
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Liposomal nanocarrier stability measurement was adapted from methods used for 
stability of doxorubicin containing liposomes [89]. Briefly, liposomal nanocarriers were 
placed in a 50% fetal bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA) 
in PBS solution to imitate blood serum.  Nanocarriers were present at a concentration low 
enough to eliminate self quenching of the dye.  The solution was placed in a 37
o
C water 
bath and samples were taken at 0, 24, and 48 hours. Leak of dye from the nanocarriers 
was assessed by measuring fluorescence of the samples at excitation 620 nm, emission 
680 nm. Percent leak was calculated as follows: 
(2) % leak = [(sample intensity)T – (sample intensity)T=0] / [(sample intensity)lysed – 
(sample intensity)T=0] 
where T is the time point, T=0 is the initial time point (representing zero leak), and lysed 
indicates a sample lysed using 0.8% Triton X-100 (Sigma-Aldrich, St Louis, MO)  
(representing 100% leak). 
3.4 Cell Culture 
3RT1RT2A (rat glioma cell line, stably expresses green fluorescent protein, GFP) 
were generously donated by Helen L. Fillmore (Virginia Commonwealth University, 
Richmond, VA).  Cells were cultured in Dulbecco's Modification of Eagle's Medium with 
4.5 g/L glucose without L-glutamine and sodium pyruvate (Mediatech, Manassas, VA), 
supplemented with 10% FBS, 1% penicillin/streptomycin (Mediatech), 1% non-essential 
amino acids (Mediatech), 1% L-glutamine (HyClone Thermo Scientific, Logan, UT), and 
1mg/ml G418 (Gemini Biosciences, West Sacramento, CA) as selective pressure for the 
GFP marker.  Primary cortical rat astrocytes were obtained and cultured as described 
previously [90]. 
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3.5 In Vitro Cell Viability 
Primary astrocytes, representing normal brain tissue, and 3RT1RT2A cells, 
representing aggressive glioblastoma, were used to assess viability of cells treated with 
nano-EB in vivo.  Astrocytes were plated at 10,000 cells per well, while 3RT1RT2A cells 
were plated at 25,000 cells/well, in tissue culture treated 24 well plates.  Cells were 
treated for 24 hours with serum free media containing either nano-EB, unencapsulated 
EB in saline, blank liposomes, or sterile saline as a control. EB dose was 0.2 mg/ml in 
both nano-EB and unencapsulated EB solutions; the dose was chosen under the 
assumption that a maximum of 2% of the liposomes delivered to an animal would reach 
the tumor based on previous work in the lab with similar liposomal nanocarriers [85].  
The lipid dose was equal in the two liposomal groups. After 24 hours, the treatments 
were removed and fresh appropriate standard serum containing cell culture medium was 
added.  Cell viability counts were taken at 0, 24, 48, and 72 hours using the CCK-8 
counting kit (Dojindo, Rockville, MD) as per the manufacturer’s instructions.  Cell 
counts were normalized to the untreated groups at each time point and reported as percent 
viable cells.  Statistical significance was determined using a 2-way ANOVA with 
Tukey’s post test using GraphPad Prism (Graphpad, La Jolla, CA). Data is presented as 
average ± standard deviation. 
3.6 Ethical Use of Animals 
All animal protocols were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee.  Fisher 344 male rats 8-10 weeks of age 
were purchased from Harlan Laboratories.  Animals were housed in a temperature 
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controlled environment with a 12 hour light/dark cycle, and were provided food and 
water for the entire duration of their housing. 
3.7 In Vivo Toxicity Testing 
Non-tumor bearing male Fisher 344 rats were injected via tail vein with sterile 
solutions of nano-EB, blank liposomes, or unencapsulated EB dye dissolved in saline. To 
ensure safety and sterility, all solutions were analyzed for correct pH and osmolarity, as 
well as tested for endotoxins (Lonza, Walkersville, MD), then filtered through a 0.2 µm 
sterile filter. Dye dose was 25 mg/kg in the two Evans blue formulations and lipid dose 
was kept equal in the two liposomal treatment groups. Mass and overall condition of the 
animals were monitored over a period of 4 weeks. 
3.8 Tumor Implantation 
Tumor implantation was adapted from Fillmore and colleagues [91].  Rats were 
anesthetized initially using 5% isofluorane and maintained at 2-3% during the entire 
procedure.  Briefly, animals were placed in a stereotactic frame, an incision was made to 
expose the skull, and a burr hole was made at the coordinates of 2 mm anterior and 2 mm 
left lateral from lambda. 3RT1RT2A GFP expressing rat glioma cells were slowly 
injected 3 mm below the surface of the skull at this position over the course of 3 minutes 
(200,000 cells in 10 µL Liebovitz L-15 medium (Invitrogen Life Technologies/GIBCO, 
Carlsbad, CA)).  Tumors were present in all animals that were injected in this way.  
Tumors implanted typically resulted in death by day 12-14; for this reason, animal 
experiments were constrained to 10 days.  
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3.9 Tumor Staining In Vivo 
On day 8 of tumor growth, animals were injected via tail vein with sterile, non-
pyrogenic solutions of 40 mg/kg EB, either as nano-EB or EB in sterile saline solution. 
Animals were euthanized 48 hours later and brains were removed and preserved in a 4% 
paraformaldehyde solution. 
3.10 Visual and Histological Analysis of Tumor Staining 
Brains of animals were removed and preserved in 4% paraformaldehyde in PBS. 
Brains were sliced coronally through the tumor and tumors were visually inspected to 
confirm presence of blue staining.  Tissue was then cryoprotected by submersion in a 
30% w/v solution of sucrose in PBS. Sections of 16 µm thickness were obtained using a 
Leica CM 300 cryostat (Leica, Bannockburn, IL). Sections were stained with anti-GFP 
monoclonal antibody conjugated with Alexa Fluor 488 (Invitrogen) to enhance green 
fluorescence and DAPI (Invitrogen) to indicate nuclei. Microscopic images of the entire 
tumor (5x magnification) were obtained and tiled together using a Axiovert 200M 
microscope (Zeiss, Thornwood, NY) with a ORCA-ER camera (Hamamatsu Photonics, 
Bridgewater, NJ) and Volocity acquisition software (PerkinElmer, Walthamm, MA). 
Images were imported to ImageJ (NIH) where background subtraction was 
performed using the included rolling ball background subtraction algorithm. Images were 
converted to 8-bit and Manders Coefficients plugin was used to find Manders 
colocalization R and M1 (red:green, indicates how much red staining is also green) [92]. 
Additionally, the 8 bit images were used to trace the tumor border as well as the Evans 
blue staining border in the nano-EB treated samples. The measure function was used to 
obtain area and perimeter of the tracing. A ratio of red area to green area and red 
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perimeter to green perimeter were calculated. Data is presented as average ± standard 
deviation. 
Higher magnification fluorescence images (10x magnification) of the tumor 
border were taken at 0, 90, 180, and 270 degrees around the border of the tumor to 




4.1 Liposomal Nanocarrier Fabrication and Characterization 
For nanocarrier fabrication, a visible dye that would produce a high contrast to 
inherent brain tissue color was desired.  Color wheel analysis showed that, other than 
black, blue and dark green offered the highest contrast to tissue encountered during 
surgery, including red (blood) and yellow/grey (healthy brain tissue). At identical 
concentrations, EB was visibly darker than any of the other dyes considered (Figure 1). 
This was confirmed by calculating perceived luminance of each dye, where a lower 
perceived luminance correlates with a darker color (values superimposed on Figure 1).  
EB had a perceived luminance value of 27, approximately 21% lower than the next 
darkest dye, Coomassie blue. Further, EB was more soluble than any of the other dyes, 
being 7 times more soluble than the next most soluble dye (EB 280g/L, Methylene blue 
40 g/L). The liposomal nanocarrier core is aqueous so high solubility in water is desirable 
for maximum loading of dye.  
Nano-EB particles were developed and characterized, assessing size, drug to lipid 
ratio, and stability.  After processing was complete, the ratio of dye to lipid was 0.08 mg 
EB to 1 mg lipid.  Average hydrodynamic diameter of nanocarriers was 173 nm with a 
polydispersity index of 0.1. Nano-EB particles were stable at body temperature (37
o
C), 




Figure 1. Candidate dyes and perceived luminance.  Dyes in solution at equal 
concentrations (m/v) and physiological pH.  From left to right: Evans Blue (chosen for 
use in our experiments), Coomassie blue, methylene blue, bromophenol blue, lissamine 
green. Perceived luminance values are provided above each dye.  Lower luminance 
correlates with darker appearance. 
4.2 In Vitro and In Vivo Toxicity Assessment 
 To ensure nano-EB had no significant cytotoxic effects against healthy cells it 
was tested against both a glioma cell line and non-malignant primary astrocytes. Nano-
EB treatment resulted in no significant changes in cell viability compared to blank stealth 
liposomes in either healthy primary astrocytes or the 3RT1RT2A glioma (Figure 2). 
 Non-tumor bearing animals were injected with either nano-EB, EB in saline, or 
blank liposomes and mass and general health of the animals were monitored for 4 weeks.  
All animals consistently gained weight after injection (Figure 3) and showed no visible 
signs of distress over the monitoring period. Animals injected with nano-EB remained 
slightly tinted blue for an average of 2 weeks post injection, while those injected with 
































































Figure 2.  Cell viability after treatment.  Cells were treated with either 0.2 mg/ml nano-
EB or EB, or blank liposomes.  Lipid dose of blank liposomes matched that of the 


































































































Figure 3.  In vivo animal growth after treatment.  Non-tumor bearing animals were 
injected with either nano-EB, unencapsulted EB, or blank liposomes.  All animals 
steadily gained weight after injections.   
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4.3 Tumor Staining and Visualization In Vivo 
Brains were sliced coronally through the center of the tumor to macroscopically 
show the extent of tumor staining evident to the naked eye (Figure 4).  Brains of animals 
given unencapsulated EB showed diffuse staining in and around the tumor, with dye 
diffusing from the tumor into the healthy tissue.  It should be noted that EB does not 
cross an intact blood brain barrier. Brains of animals given nano-EB only had staining in 
the region of the tumor.   
 
Figure 4.  Coronal slice of brains of tumor bearing animals. Animals were treated 
with nano-EB (left) or EB (right). Scale bars = 1mm  
Besides its contrasting blue color, EB also fluoresces red, making high 
magnification microscopic analysis possible. Fluorescence microscopy was performed to 
confirm that nano-EB did not stain healthy tissue (Figure 5). Manders coefficient analysis 
was performed on tiled whole tumor images, comparing green fluorescence from GFP 
expressing tumor cells with red fluorescence of the nano-EB (results in Table 1). Average 
overall Manders R was found to be 0.51 ± 0.08 (n=3 animals, 3 slices per animal).  M1 
(red:green) was found to be 0.97 ± 0.06, indicating that 97% of the red fluorescence 






Figure 5.  Microscopic analysis of staining. Whole tumor stitch, 5x magnification. 
(Top) Tumor of nano-EB treated animal. Green indicates tumor cells (GFP). Red 
indicates EB. Arrows indicate invasive clusters of cells marked by nano-EB. (Bottom) 




Further analysis compared the total area of the tumor to that of the nano-EB 
stained tissue to get an indication of how much of the total tumor was stained. Ratio of 
red area to green area averaged 0.89 ± 0.05.  The ratio of perimeter of the same slices was 
0.94 ± 0.04.  Numbers close to but not greater than 1 indicate that the nanocarrier staining 
of tissue always stayed within the tumor tissue.  Lack of healthy tissue staining was 
confirmed by visually inspecting high magnification (10x) images of the tumor border in 
nanocarrier treated animals (Figure 6).  
 
 
















 .89 ± .05 .94 ± .04 .51 ± .08 .97 ± .06  
 
*
Area ratio = area red (nano-EB) / area green (3RT1RT2A glioma cells, GFP).   
**
Perimeter ratio = perimeter red/perimeter green.    
#
Manders R indicates the amount of colocalization of red and green throughout the tissue.   
##
M1 indicates how much tissue stained red is also stained green.   







Figure 6. Tumor Border Images of nano-EB treated animals. (Top) Tumor (GFP) 






DISCUSSION AND CONCLUSION 
5.1 Discussion 
Complete resection of tumor is essential to successful treatment of gliomas. 
Currently, once resection has begun, the surgeon has limited ability to distinguish the 
margin of the tumor, relying on subjective criteria such as tactile feedback and slight, 
often indistinguishable, color differences between healthy and tumor tissue.  Thus, it 
would be beneficial to have an objective means to distinguish the tumor margin visually 
for the neurosurgeons in the OR.  Other approaches include staining tumors using 
fluorescent molecules, but these require specific lighting conditions since the halogen 
lights typically used in surgical environments often emit radiation in the wavelengths that 
causes interference with fluorescence detection, as well as extra equipment and training 
[11-15]. In response, non-fluorescent dyes have been tested, though these compounds 
were only tested in non-invasive tumor models, which may not adequately represent their 
use clinically [16, 17]. 
Here, we demonstrate that freely circulating small molecule compounds, such as 
Evans blue dye, diffuse out of the tumor and in to healthy tissue complicating their ability 
to help demarcate the margins between tumor and healthy tissues. We proposed the use 
of a nano-scale encapsulation of a visible dye to provide the objective criteria that 
surgeons need to consistently and correctly distinguish tumor tissue from healthy tissue 
without the need of specialized equipment, lighting, or extra training on new equipment.   
Intravenous injection of liposomal nanocarriers containing Evans blue dye clearly 
marked the tumor and its margins, as well as small nodules of invasive cells that had 
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invaded beyond the bulk tumor border. A Manders coefficient of 0.6 or higher is 
generally accepted as indicating true colocalization in fluorescence microscopy [93]. In 
our experiments, we obtained Manders coefficients that appear low at 0.51±0.08, but this 
was to be expected. Little endocytosis by cancer cells of the nano-EB occurs at the time 
scale used (48h). Therefore, most would be present extracellularly and thus not overlap 
with cytoplasmic GFP.  
An important measure obtained from overlap coefficient analysis is the M1 
(red:green) of 0.97, indicating that nearly all area that was stained red was also stained 
green. This indicates that nanocarriers stained only tumor tissue. The area and perimeter 
ratio analysis further confirmed that the nanocarriers only stained tumor tissue. Higher 
magnification microscopic examination of the border also confirmed that only tumor 
tissue was stained, with nanocarriers slightly and consistently underestimating the true 
margin on the order of tens to hundreds of micrometers. This is sufficient considering 
surgeons often remove tissue in sections with thicknesses on the order of millimeters, 
several orders of magnitude greater than the underestimation [94].  It is important to note 
that healthy tissue was not stained, preventing false positives and removal of healthy 
tissue by the surgeon.  
The amount of leak of dye from the liposomes over the 48 hour period after 
injection was consistent with previously reported clinically used liposomal nanocarrier 
formulations [72, 95, 96].  It should be noted that even with this slight leak the nano-EB 
did not stain healthy tissue. Evans blue is a strongly polar molecule; leaked dye quickly 
binds to blood serum proteins, limiting its diffusion [97].   
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Evans blue dye was initially FDA approved for use in blood volume 
measurement. It was later found to be toxic in repeated use or large doses [98, 99]. 
However, the negative side effects are usually reduced and pharmacokinetics of 
molecules are drastically changed when they are encapsulated in liposomal nanocarriers 
[21-23, 85]. The encapsulation of molecules creates a barrier and reduces their ability to 
interact with non-target tissues.  For example, the nanoencapsulation of doxorubicin in 
liposomes known as Doxil®; cardiotoxicity is greatly reduced in Doxil® when compared 
to free drug [22, 23].  
In vitro, nano-EB did not have a negative effect on the viability of either the 
tumor cell line (3RT1RT2A) or their healthy counterpart, primary astrocytes. Intravenous 
injections of either nano-EB or EB had no negative effect on the growth of animals 
treated, nor did it cause any visible signs of distress in the animals. This was to be 
expected since the doses used were much lower than those seen as toxic in published 
studies [98, 99]. Emphasis should be placed on further testing to determine the safety of 
such a nanocarrier for clinical use.  
Our data demonstrates that tumor margins may be reliably and accurately 
demarcated by eliminating the staining of healthy tissue seen when small molecule dyes 
are used in an invasive tumor model. It also demonstrates that nanocarriers carrying 
visible dyes localize to tumor margins facilitating both the accurate resection of the tumor 
and accurate sparing of healthy tissue.  
5.2 Conclusion 
 Liposomal nanocarriers containing visible dye Evans blue (nano-EB) successfully 
stain invasive tumors in vivo, creating clear visible distinction between tumor and healthy 
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tissue. A nanocarrier is not only preferred but also necessary; injection of unencapsulated 
dye results in staining of healthy tissue in an invasive tumor model.  Invasive models are 
more clinically relevant than non-invasive models such as 9L. Use of such a nanocarrier 
would allow surgeons to intraoperatively distinguish tumor tissue from healthy, likely 
increasing extent of resection, and thus result in a better prognosis for the patient while 





6.1 Dose and Time Point Optimization 
 The dosing in this study was not optimized for maximum staining while 
minimizing side effects, such as coloration of the animal.  Basically, it was a brute force 
method used in order to get the desired result.  The maximum volume injection was used 
with the maximum concentration of liposome encapsulated EB possible.  In theory, the 
same results could be reached using much lower doses.  PEG coated liposomes typically 
circulate for long periods of time, with half lives on the order or 1-3 days.  Longer 
circulation times allow for higher accumulation in tumor tissue based on probability.  The 
more times a particular liposome passes by the fenestrated vasculature in the tumor, the 
more likely it is to extravasate into the tumor interstitium.  Therefore, if dose is reduced 
and time before surgical intervention is increased, similar results could be seen.  Lower 
dose would decrease the blue tinting of the patient, as well as reduce likelihood of toxic 
side effects. 
This approach, however, is limited by the leakiness of the liposomes themselves.  
If too much time is allowed, encapsulated dye would leak out in large enough 
concentrations that dye would diffuse into healthy tissue.  The result would be healthy 
tissue staining and false positive marking, much like what is seen when unencapsulated 
Evans blue dye is injected. 
During this study, the timepoint of 48 hours was chosen based on literature 
demonstrating the long circulating characteristics of similar formulations of liposomes {.  
However, these were either drug delivery or contrast enhanced non-invasive imaging 
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studies, so they do not necessarily apply here when visible contrast is the metric.  
Research should be done to assess the optimal time for sufficient accumulation to ensure 
visible contrast. 
6.2 Nano-EB Staining in Other Tumor Models 
Above, we have shown that a nanoencapsulated visible dye will accurately and 
reliably stain an invasive tumor without staining healthy tissue.  However, this was only 
done in one animal model of rat glioma, RT2.  Though RT2 is a well known clinically 
relevant form of invasive glioma, it would be necessary to show effectiveness in other 
tumor models.  This should include other models in the rat, including the non-invasive 9L 
model used by fellow researchers attempting to develop visible dyes to stain brain 
tumors.  Models of medulloblastoma and other malignant tumors of the CNS should also 
be considered.  Future research should also include tumor models in higher organisms. 
The presented method could be used in other tissues as well to mark tumors.  
Kaposi’s sarcoma is a highly malignant skin cancer that is currently treated with 
liposomal doxorubicin.  It is likely that nano-EB would effectively stain these lesions for 
resection.  It is likely the method would not work in tissues such as the liver and spleen.  
One of the many jobs of the liver is to filter macromolecules out of the blood.  The spleen 
is part of the MPS, a system responsible for removing macromolecules throughout the 
body.  Therefore, excess nano-EB liposomes accumulate in these tissues.  As a result, the 
healthy regions of the tissues themselves would be stained blue so there would not be 
sufficient contrast between tumor tissue and background accumulation in these tissues.  
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6.3 Reducing Production Time and Waste 
 The manufacturing process by which the nano-EB particles were made is very 
time consuming, messy, labor intensive, and produces a lot of waste.  Evans blue dye was 
dissolved at 75 mg/ml in the initial solution to ensure the maximum possible loading of 
the aqueous core of the liposomes.  The unencapsulated dye then had to be removed to 
avoid healthy tissue staining in vivo.  Several purification techniques were attempted, 
including dialysis, diafiltration, high speed centrifugation, and spin columns, but only 
size exclusion chromatography columns proved sufficient to nearly completely remove 
unencapsulated dye.  Even though the technique worked, it required multiple passes of 
the crude liposome mixture through the separation column to ensure enough dye was 
removed so that the nanocarriers could be used in vivo.   Also, column chromatography is 
not conducive to scale up.  Generally diafiltration is the optimal scalable process for 
purification of liposomes for the large scale manufacturing processes necessary for a 
product to be used in clinic. Though it would require synthesis of a new dye molecule, 
excess wasted dye could be reduced if an active loading scheme were used opposed to the 
passive scheme currently employed. 
 Loading of doxorubicin into liposomes is an example of active loading.  This 
method was first published by Bolotin et al in 1994 [100].  First, liposomes are 
manufactured so that they contain acidic (pH~5 - 5.5) ammonium sulfate in their aqueous 
core.  Then, doxorubicin is placed into the liposome suspension and heat is applied to 
cause the lipid bilayer to become fluid-like.  Doxorubicin is initially amphipathic, 
allowing it to freely pass through the lipid bilayer into the aqueous core of the liposomes 
(Figure 7).  When the molecule enters the slightly acidic core of the liposome, the 
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neutrally charged –NH2 gains a hydrogen atom and becomes –NH3
+
.  The newly formed 
positive charge ionically associates with sulfate (SO4
-
) present in the liposome core to 
form an insoluble precipitate.  Thus, governed by the law of mass action, the reaction 
equilibrium is constantly driven to create more precipitate until either doxorubicin or  
sulfate ions are exhausted.  A similar scheme could be employed using a dye similar to 
Evans blue, but with the properties of doxorubicin (an amphipathic molecule at neurtral 
pH that would gain a positive charge when exposed to lower pH).  
Figure 7.  Ammonium sulfate gradient loading scheme for doxorubicin. 
6.4 Developing a Dual Mode Nanocarrier 
 It would be beneficial if the nanocarrier could not only provide intraoperative 
delineation, but could also be used for non-invasive contrast enhancement of tumor for 
preoperative surgical planning.  MRI is often used to provide a topographic map of the 
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brain and location of the tumor, which surgeons use to plan out their resection procedure.  
Thus, a nanocarrier that could provide MRI enhancement is desireable.  Currently, it is 
common to use unencapsulated gadolinium (Gd) chelates to provide contrast for MRI for 
many applications, including tumor contrast enhancement.  Development of such a 
nanocarrier would be straight forward. 
Phospholipids that are conjugated to Gd chelates are available for purchase.  
Ghaghada et al. used such phospholipids to demonstrate effectiveness incorporating these 
phospholipid Gd chelates into liposomes for in vivo MRI imaging [101].  Manufacturing 
would be simple, only adding a few steps to the current manufacturing process.  
Essentially, one would manufacture the liposomes as presented in the methods section, 
then the Gd chelates can be post-inserted, similarly to the methods used by Saul et al to 
post insert folate conjugated phospholipids into liposomes [84]. 
A dual mode nanocarrier capable of MRI contrast as well as intraoperative tumor 
border delineation would allow for both to be performed after a single injection.  
Pharmacokinetics should be similar to nano-EB since the MW of the PEG chains is much 
larger than that of the Gd chelate.  The chelate would be shielded from the MPS much 
like the surface of the liposome itself so opsonization and clearance will be slowed. 
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